Skip to main content
Caplight Logo









LabGenius Therapeutics

LabGenius Therapeutics

Private
LondonHealthcare & Life Scienceshttps://labgeniustx.com/

Last Round

Series B

Extension

Feb 16, 2026

Total Funding Raised

$78.1M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

LabGenius Therapeutics is a biotechnology company that develops an AI-driven protein engineering platform to discover and optimize next-generation therapeutic antibodies for solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Application

Keywords

antibody discoveryprotein engineeringdrug discoveryAI drug discoveryin silico drug designmultispecific antibodiesclosed-loop discoverysynthetic biologyrobotic automationmachine learningbiotech platformoncology therapeuticslab automationcomputational biologybiopharma R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

LabGenius Therapeutics Comparables

Compare LabGenius Therapeutics with similar companies based on industry and business-model similarity.

LabGenius Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
BigHat Biosciences
88%
Generate Biomedicines
83%
AbCellera Biologics Inc.
83%

LabGenius Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionFeb 16, 2026
Series BMay 21, 2024
GrantNov 30, 2022
GrantOct 7, 2022
Series A ExtensionOct 29, 2020
Series A
Oct 24, 2019

Key People

Founding team and executive leadership

James Field

CEO & Founder

Founding Team

LabGenius Therapeutics Investors

Notable investors and investment history

LabGenius Therapeutics investors
InvestorRounds
Innovate UKGrant
Backed VCSeed
Beast ModeSeed
System.OneSeed
Inovia CapitalSeries A, Series A Extension
Air Street CapitalSeries A
Acequia CapitalSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 95% MoM, reaching 4.2K.

  • Apr 25, 2026

    Monthly visitors increased 180% MoM, reaching 3.1K.

LabGenius Therapeutics Filings

Explore SEC and related filing metadata, where available.

LabGenius Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about LabGenius Therapeutics's valuation, stock price, and market status.

Is LabGenius a public or private company?

LabGenius is a private company.

What is the current stock price of LabGenius?

LabGenius is a private company with no public stock price. No recent secondary market data is available.

How much is LabGenius worth (valuation)?

Valuation information for LabGenius is not publicly available.

Can I buy LabGenius stock?

LabGenius shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was LabGenius's last funding round?

LabGenius's most recent funding round was Series B on May 21, 2024.

Who are the main investors in LabGenius?

Key investors in LabGenius include Lux Capital, Obvious Ventures, Kindred Capital, Atomico, Acequia Capital.

Will LabGenius IPO soon?

No public IPO plans have been announced for LabGenius.

How can I track LabGenius secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor LabGenius's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLondon
Employee Range62
Year Founded2012
Last FundingFeb 16, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?